Forte Biosciences for approximately $2.2bn in total equity value. Approved by both companies’ boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon ...

Apnimed will use the IPO funds to progress lead candidate oxnimbi, which could become the first pill to break onto the OSA market.

Wet AMD is an eye disorder characterised by leaky vessels in the retina causing vision loss. Credit: PeopleImages/Shutterstock.com. Following years of regulatory setbacks that saw multiple rejections, ...

Misumi Americas makes US manufacturing strategic priority, the celebrity brand ambassador rise in pharma, AI in the hospital pharmacy, and more.

BMS enhances its AI computing power with NVIDIA's DGX SuperPOD as big pharma race to stay competitive within the shifting global landscape.

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and ML.

Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugma ...

BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.

Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.

Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.

In a lawsuit filed in the US, Novo alleged that Lilly’s campaign was designed to mislead consumers on “comparative efficacy” of drug brands.